Glioblastoma (GBM, Grade IV astrocytoma) is the most common and most aggressive of the primary malignant brain tumors in adults. Hypoxia is a distinct feature in GBM and plays a significant role in tumor progression, resistance to treatment and poor outcomes. This review considers the effects of hypoxia on astrocytic tumors and the mechanisms that contribute to tumor progression and therapeutic resistance, with a focus on the vascular changes, chemotaxic signaling pathways and metabolic alterations involved.
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© (Howlader et al., 2014) . In 2015, an estimated 23,180 new cases of primary malignant brain tumors will be diagnosed and 16,570 patients will die from these tumors (Ostrom et al., 2014a (Ostrom et al., , 2014b . While essentially any neuroepithelial cell in the brain can develop into a malignancy, astrocytes are the most common cell of origin for malignant brain neoplasms accounting for approximately two thirds of malignant CNS tumors. Primary brain tumors that develop from astrocytes are called astrocytomas. The World Health Organization (WHO) classifies astrocytomas into four distinct grades (I-IV) on the basis of their microscopic appearance. Collectively, the grade III and IV gliomas are referred to as high grade gliomas, with grade IV referred to as glioblastoma. With the exception of the rare grade 1 (pilocytic) astrocytoma, these tumors are considered incurable and progress in grade and aggressiveness with time from diagnosis. In fact, nearly 90% of astrocytoma present de novo as a glioblastoma. Once transformation to, or diagnosis of glioblastoma occurs, survival is quite poor, and with best available care the median survival is approximately 16 months with a 5 year survival rate of 3.3% (Ostrom et al., 2014a (Ostrom et al., , 2014b .
The poor survival is attributable partly to the nature of the tumor. The infiltrative nature of GBM results in difficulty eliminating microscopic disease despite macroscopic gross-total resection, with 90% of patients having recurrence at the original tumor location (Hou et al., 2006) . The location of the tumor also makes drug delivery difficult with only small or lipophilic molecules able to cross the blood brain Neurobiology of Disease 85 (2016) 227-233 
